简体中文English

p53/[CCND1/IGH]/ATM/CSP12/D13S25 gene probe reagent
Wholesale Price(RMB):

1200024000132002640013200264001440028800

Product Code:R-0501415Ⅰ-01/R-0501415Ⅰ-02/R-0501415Ⅱ-01/R-0501415Ⅱ-02/R-0501415Ⅲ-01/R-0501415Ⅲ-02/R-0501415Ⅳ-01/R-0501415Ⅳ-02
Probe name:Hybridization Solution I: CSP 17 / GSP p53; Hybridization Solution II: GSP CCND1 / GSP IGH; Hybridization Solution III: GSP ATM / CSP 11; Hybridization Solution IV: GSP D13S25 / CSP 12
Product Code:Type I (direct FISH method)/Type II (biotin-labeled indirect FISH method)/Type III (digoxigenin-labeled indirect FISH method)/Type IV (TSA-FISH method)
Registration Number:
Clinical Value

The NCCN recommends the use of cytogenetic techniques (conventional karyotyping or FISH) to detect chromosomal abnormalities such as t(11;14), t(11q;v), +12, del(11q), del(13q), del(17p), etc., for the initial diagnosis of chronic lymphocytic leukemia CLL;


Chromosomal abnormalities are present in approximately 80% of CLL patients, and these abnormalities are important for the diagnosis, differential diagnosis, selection of treatment options, and prognosis of CLL;


CLL patients with del(13q) alone have a better prognosis. Chromosomally normal and +12 have a moderate prognosis, while patients with del(11q) or del(17p) have a poor prognosis. In particular, patients with del(17p) have the worst prognosis;


New genetic abnormalities may be acquired during disease progression, and cytogenetic evaluation should be performed again in patients with disease progression, relapse, and drug resistance before starting new therapy;


Patients with therapeutic indications are stratified according to FISH results and different treatment options are selected.